Centessa Pharmaceuticals(CNTA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 • ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH • ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year • ORX489 in IND-enabling studies for the treatment of neuropsychiatr ...